Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Phathom Pharmaceuticals (PHAT), Oncology Institute (...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Alison Fok from DBS maintained a Hold rating on Stella International Holdings Limited, with a price target of HK$14.20....

DBS Remains a Hold on Stella International Holdings Limited (SLNLF)

The latest update is out from Southland Holdings ( ($SLND) ). On June 10, 2026, Southland Holdings, Inc. held its 2026 annual meeting of stockholde...

Southland Holdings Shareholders Back Board and Auditor Choices

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX), DENTSPLY SIRONA (XRAY) an...

Silence Therapeutics ( ($SLN) ) has shared an announcement. On June 11, 2026, Silence Therapeutics reported follow-up and quality-of-life data from...

Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data

Basilea Pharmaceutica ( ($CH:BSLN) ) has issued an announcement. Basilea Pharmaceutica has secured an additional USD 13.3 million in non-dilutive f...

Basilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Silence Therapeutics today and set a price target of $75.00. Trucchio covers th...

Silence Therapeutics (SLN) Receives a Buy from H.C. Wainwright

Finnish smart ring creator Oura is circling towards an $11 billion initial public offering (IPO) in the U.S. Valuation Has Doubled The company, who...

Market Cap	$314.03M	P/E Ratio	N/A
52W High	$8.40	52W Low	$4.19
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-115.4%	52W Position	79.3%
Overall Score	67	Value Score	40
Quality Score	71	Technical Score	90

EPS Current Est	$-0.95	EPS Next Est	$-1.46
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$7.53	+8.66%	354.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$7.53	+8.7%	354.50K
3
4
5
6

SLN

SLN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Silence Therapeutics Plc Data in Excel

Get Silence Therapeutics Plc Data in Excel